All News
Filter News
Found 809,065 articles
-
Rainier Therapeutics Announces Appointment of Gary Christianson as Chief Technical Officer
5/1/2019
Rainier Therapeutics, Inc., a privately held clinical stage drug development company, today announced the appointment of Gary Christianson, PE, as Chief Technical Officer.
-
FDA approves Dengvaxia® for the prevention of dengue in individuals ages 9 through 16 living in U.S. endemic areas
5/1/2019
The U.S. Food and Drug Administration approved Dengvaxia® for the prevention of dengue disease caused by serotypes 1 – 4 of the virus in individuals 9 through 16 years of age living in endemic areas of the U.S. with a laboratory-documented prior infection.
-
Clinigen Appoints James Meyer as General Manager of Commercial Medicines in the US
5/1/2019
Jim Meyer is an accomplished and seasoned executive with nearly 40 years of experience in the pharmaceutical industry
-
Teva to Present New Central Nervous System Portfolio Data at 71st Annual Meeting of the American Academy of Neurology
5/1/2019
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the Company will present data at the 71st Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia from May 4-10, 2019
-
Advanced Medical to be acquired by AMN Healthcare
5/1/2019
This strategic acquisition brings forth a tremendous opportunity of growth and value for our client base, network of healthcare professionals, and Advanced employees.
-
Quidel to Present at the Bank of America Merrill Lynch Health Care Conference 2019
5/1/2019
Quidel Corporation announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2019, to be held at the Encore at Wynn hotel in Las Vegas, Nevada on Thursday, May 16, 2019.
-
Brink Biologics Announces Research License Agreement with Worcester Polytechnic Institute for Use of NantKwest’s NK-92® Cells
5/1/2019
Brink Biologics, Inc., a NantKwest, Inc. (Nasdaq:NK) affiliate who serves as exclusively-licensed distributor of NantKwest’s proprietary NK-92® natural killer cells, offers a variety of research grade aNK™ and haNK® cell lines for non-clinical laboratory use in discovery, translational and developmental research and lot release testing for commercial products ranging from monoclonal antibodies, bi-specific biologics, cytokines and other bioactive products.
-
Paul G. Allen Family Foundation Announces Winners of Ebola Response Accelerator Challenge
5/1/2019
Grantee projects focus on community engagement; Foundation total funding now at almost $4M for current Democratic Republic of Congo outbreak
-
Biocept to Release First Quarter 2019 Financial Results and Host Investor Conference Call on May 8, 2019
5/1/2019
Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable information to physicians to improve the outcomes of patients diagnosed with cancer, announces that it will release financial results for the three months ended March 31, 2019 after the market closes on Wednesday, May 8, 2019.
-
Repare Therapeutics Appoints Dr. Maria Koehler as Chief Medical Officer, Katina Dorton as Chief Financial Officer and Carol Schafer to its Board of Directors
5/1/2019
Repare Therapeutics, a precision oncology company pioneering synthetic lethality to develop novel therapeutics that target specific vulnerabilities of tumors in genetically defined patient populations, announced today that it has made three key additions to its leadership team and Board of Directors
-
New Etactics' Solution Introduces Accurate, Simple, Mobile Friendly Address Correction
5/1/2019
Exact and Exact Plus pairs address correction services for statements and invoices with an entirely new user interface that's designed with portability in mind
-
Inovio Pharmaceuticals to Report First Quarter 2019 Financial Results on May 9, 2019
5/1/2019
Following the release, the Company will host a conference call and live webcast at 4:30 p.m. ET, to provide a general business update and financial results for the first quarter 2019.
-
Tetra Discovery Partners Initiates Phase 2 Clinical Trial of BPN14770 in Patients with Early Alzheimer’s Disease
5/1/2019
Tetra Discovery Partners, a clinical-stage biotechnology company, today announced the initiation of a Phase 2 clinical trial (PICASSO AD) of BPN14770 in patients diagnosed with early Alzheimer’s disease (AD).
-
Sunovion to Present Data on LONHALA® MAGNAIR® Inhalation Solution and COPD at the American Thoracic Society International Conference 2019
5/1/2019
Sunovion Pharmaceuticals Inc. (Sunovion) will present data from its portfolio of treatments for chronic obstructive pulmonary disease (COPD) at the American Thoracic Society International Conference 2019 (ATS 2019), taking place May 17-22, 2019 in Dallas, Texas.
-
Vital Decisions Expands its Advanced Care Alignment Telehealth Program
5/1/2019
Health plan members who are eligible for Vital Decisions' Advanced Care Alignment benefit, and their families, now are able to choose to have video-based sessions from any device with their Vital Decisions clinical Specialist.
-
Prompt diagnosis is key to preventing patients from developing chronic Lyme disease
5/1/2019
MyLymeData Highlights Report says early treatment offers best chance of recovery
-
Blue Matter Launches New Company, Salience Learning
5/1/2019
The new company is a learning and development (L&D) firm focused on the life sciences.
-
Walgreens Forms Unique Collaboration with National Council for Behavioral Health and American Pharmacists Association to Offer Mental Health First Aid Training for Pharmacists and Team Members
5/1/2019
As the most accessible health care providers in the community, and also among the most trusted, pharmacists can play an important role as part of patients’ care teams to help address the growing need for mental health resources.
-
Bayer Launches Test Your Cancer Campaign Empowering Patients to See the Real Picture through Genomic Cancer Testing
5/1/2019
Bayer announces the launch of Test Your Cancer, a global educational campaign that harnesses the creative power of imagination to help cancer patients better understand that genomic cancer testing is a crucial step in a diagnosis, painting a more precise picture of a person's individual cancer.
-
Arcadia Biosciences Announces Date of First-Quarter 2019 Financial Results and Business Highlights Conference Call
5/1/2019
Plans to release its first-quarter 2019 financial and business results after market close on May 8, 2019.